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Abstract
Background: Neutral endopeptidase (NEP), an enzyme that cleaves inflammatory bioactive peptides, may play a
protective role in the pathogenesis of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).
However, its low extracellular activity hinders the precise measurement of changes that take place during
ALI/ARDS. The main objective of this study was to clarify the regulation of NEP activity and its expression during
ALI/ARDS.
Methods: In a clinical study, we measured plasma NEP activity in patients who developed postoperative ALI/ARDS,
using a HPLC fluorometric system. In an experimental study, we induced ALI by intratracheal instillation of
hydrochloric acid (HCl) or lipopolysaccharide (LPS) in mice, and similarly measured NEP activity in plasma, lung
tissue, and broncho-alveolar lavage fluid (BALF). We also studied the distribution and measured the amounts of
NEP protein, using immuno-histochemical and immunoblot analyses, and measured the levels of NEP mRNA, using
real-time reverse transcription-polymerase chain reaction, in the lungs of mice with ALI.
Results: The plasma NEP activity was significantly lower in patients presenting with ALI/ARDS than in controls.
Similarly, the NEP activity in plasma and lung tissue was markedly lower, and lung injuries more severe in LPS-
than in HCl-treated mice. In contrast, the activity of NEP in the BALF of LPS-treated mice was increased. The
intratracheal instillation of LPS decreased the gene expression of NEP in the lung. Immuno-histochemical and
Western immunoblot studies in mice confirmed a) the presence of NEP in the alveolar wall, a critical target in ALI/
ARDS, and b) a decrease in its expression in HCl- and LPS-induced ALI.
Conclusion: In this experimental and clinical study of ALI/ARDS, the activity of NEP was significantly decreased in
plasma and increased in the alveolar air space.
Background
Acute respiratory distress syndrome (ARDS), the most
severe form of acute lung injury (ALI), is associated with
an up to 35% mortality rate, despite intensive care [1,2].
Severe sepsis, pneumonia, acid aspiration, and surgical
stress are the major causes of ALI/ARDS, which disrupt
the alveolar-capillary membrane barrier and induce pul-
monary edema associated with proteinaceous alveolar
exudates and deterioration of gas exchange [3]. While
several biological mediators are known to make impor-
tant contributions to its development, the interactions
among cellular and soluble mediators responsible for
ALI/ARDS are complex and incompletely understood.
Neutral endopeptidase (NEP; EC 3.4.15.1), also known
as enkephalinase, neprilysin, common acute lymphoblastic
leukemia antigen (CALLA) or CD10, is a membrane-
bound zinc-metallopeptidase enzyme that regulates the
physiological action of various peptides, including
natriuretic and bombesin-like peptides, endothelin-1, and
substance P [4-6]. The involvement of NEP in the limita-
tion of pro-inflammation has been studied, using selective
inhibitors and gene deletion in mice. NEP-deficient mice
develop exaggerated LPS-induced endotoxic shock [7] and
acute pancreatitis-associated lung injury [8]. The pharma-
cological inhibition of NEP exacerbates ALI in mice pre-
senting with fire-smoke and fire-burn injuries [9]. Recent
studies have also found a decreased NEP activity partici-
pating in vascular permeability and edema formation in
the lung [9,10]. Other metallopeptidases present in the
lung, such as angiotensin- and endothelin-converting
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inversely implicated in the development of ALI/ARDS
[11-13].
While evidence is accumulating of an important pro-
tective role played by NEP, the measurements of its activ-
ity in ALI/ARDS have been ambiguous, probably because
of the low sensitivity of conventional photometric mea-
surements. A deeper understanding of the regulation of
NEP activity in ALI/ARDS would yield valuable mechan-
istic information. Thus, the objectives of this study were
to 1) measure the activity of NEP in clinical and experi-
mental lung injury, and 2) clarify the systemic and intra-
alveolar regulation of NEP activity in ALI/ARDS, using a
newly developed high-sensitivity measurement system.
Methods
Patient population
The clinical study was conducted in the general inten-
sive care unit of the Kyoto Prefectural University of
Medicine Hospital, using protocols approved by the
Ethics Committee on Human Research. We studied 8
randomly selected patients, who underwent total thor-
acic esophagectomy and reconstruction with a retroster-
nal stomach tube for esophageal cancer. Diagnoses of
ALI or ARDS were made on the basis of the definitions
formulated by the American European Consensus Con-
ference [14]. A lung injury score was also calculated for
each patient, according to published algorithms [15].
Blood samples were collected in sterile heparinized
tubes and centrifuged at 500 g for 10 min. Plasma sam-
ples were stored at -80°C until analysis.
Animal preparations
Male specific pathogen-freeI C Rm i c e ,6 - 8w e e k so fa g e ,
were obtained from Japan SLC Inc., Shizuoka, Japan. The
mice were housed under standard laboratory conditions
and allowed free access to food and water. All procedures
were carried out in compliance with the guidelines
approved by the Institutional Animal Care and Use Com-
mittees of Kyoto Prefectural University of Medicine.
Induction of lung injury
The mice were anesthetized with sevoflurane, and
received a single intratracheal instillation of 2 ml/kg of
normal saline, or 0.1 N hydrochloric acid (HCl), or
10 mg/kg lipopolysaccharide (LPS) in 2 ml/kg of normal
saline, using a previously described procedure [16]. The
HCl-treated animals were sacrificed at 4 h, and the LPS-
treated or control mice were sacrificed at 24 h after
instillation, all under deep anesthesia with sevoflurane.
Lung histology and immunohistochemistry
Paraformaldehyde-fixed, paraffin-embedded sections of
mouse lung tissue were prepared and stained with
hematoxylin and eosin. The microscopic slides were
examined by an investigator unaware of their origin, who
assigned a lung injury score in 4 categories, including the
thickness of the alveolar septa, presence of alveolar
hemorrhage, formation of hyaline membrane, and pre-
sence of intra-alveolar infiltrates. The severity of injury
was judged according to a previously published scoring
system [17], between 0 = no or minimal injury, 1 = mild
injury, 2 = moderate injury, 3 = severe injury, and 4 =
maximum injury. For the immuno-histochemistry, the
antigen was retrieved with citrate buffer and the tissue
blocked with 1% H2O2, avidin, biotin, and mouse-on-
mouse blocking reagent (Vector Lab, Burlingame, CA), as
appropriate. The sections were incubated with mouse
anti-NEP (Mitsubishi Chemical Co., Tokyo, Japan) fol-
lowed by a biotinylated secondary antibody. The signals
were detected by the ABC method (Vector), followed by
diaminobenzidine (Dako Japan Ltd., Kyoto, Japan). The
slides were counterstained with hematoxylin.
Lung water content
The lung water produced by the injury was measured,
using the lung wet/dry (W/D) weight ratio. The right lobe
was dissected, weighed immediately after removal, and
dried for 5 days in an oven at 60°C. The lung W/D weight
ratio was calculated as the ratio of wet to dry weight.
Broncho-alveolar lavage analyses
The broncho-alveolar lavage consisted of 2 washes with
1.0 ml of phosphate buffered saline. The broncho-alveolar
lavage fluid (BALF) was centrifuged at 400 g for 10 min,
and the cell pellet was resuspended in 1.0 ml of phosphate
buffered saline. The total number of cells in the lavage
fluid was counted with a hemocytometer. Cell differentials
were counted on cytospin preparations stained with Diff-
Quik (Sysmex, Kobe, Japan). At least 200 cells per sample
were counted under light microscopy. The cytospin
preparations from the lavage were also fixed with 4%
paraformaldehyde for 10 min, followed by immuno-
cytochemical staining for NEP as described earlier. The
cell-free supernatant of BALF was immediately stored at
-80°C for total protein and NEP activity assays.
Measurements of NEP activity
The NEP activity was measured as described previously
[18]. An aliquot of each humoral sample was incubated
with 200 μM of Dansyl-D-Ala-Gly (DAG) p-nitro-Phe-Gly
(NPG) in presence or absence of 10 μMo ft h i o r p h a n ,a t
37° C for 60 min. The enzymatic reaction was terminated
by heating at 90° C for 3 min. After brief centrifugation,
an aliquot of the supernatant was analyzed by HPLC-
fluorometry. The fluorescence intensity of DAG separated
from the fluorescence of the substrate was measured,
using a RF-10AXL, fluorescence detector for HPLC
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gel column (GL Science), with a guard column was used
for the assay. The injected sample was eluted with 40%
acetonitrile containing 0.05% trifluoroacetic acid, at a flow
rate of 0.5 ml/min at 40° C. The amount of product was
estimated by measuring its fluorescence intensity at 562
nm (Em) with excitation at 342 nm (Ex). For measure-
ments of NEP activity in mouse lungs, each specimen was
homogenized with 5 volumes of 50 mM homogenate
HEPES buffer at pH 7.4, containing 1 mM ethylene glycol
tetraacetic acid, 50 μM phenylmethylsulfonyl fluoride, 1
μg/ml pepstatin and 1 μg/ml leupeptin, and centrifuged at
1,000 g for 5 min. An aliquot of supernatant was incu-
bated with this homogenate buffer containing 200 μMo f
DAGNPG, at 37°C for 30 min, and the fluorescence inten-
sity of DAG was measured as described earlier. The speci-
fic NEP activity was estimated after the measurement of
protein concentration in each sample, according to the
method of Bradford.
Immunoblot analysis
We added 25 μg of protein to Laemmli sample buffer,
boiled for 5 min. The proteins extracted from each lung
t i s s u ew e r ee l e c t r o p h o r e s ed on 12.5% sodium dodecyl
sulfate-polyacrylamide gels followed by transfer to a
polyvinylidene fluoride membrane (Millipore, Bedford,
MA). A horseradish peroxidase-conjugated secondary
antibody and ECL™ Advance Detection Kit (GE Health-
care Bio-Sciences, Piscataway, NJ) were used for immu-
nodetection. b-actin (Santa Cruz Biotechnology, Santa
Cruz, CA) was used as loading control, and the intensity
of the NEP signal was semi-quantified from scanned
immunoblots, using Adobe® Photoshop® software
(Adobe Systems Inc., San Jose, CA).
Real-time polymerase chain reaction
Total RNA was extracted from lung tissue using a TRI-
zol® reagent (Invitrogen Life Technologies, Carlsbad,
CA). Total RNA was reverse-transcribed to cDNA with
SuperScript® III (Invitrogen) first-strand synthesis for
real-time reverse transcription (RT) -polymerase chain
reaction (PCR). The primer sequences for NEP and 18 S
rRNA are available upon request (Takara Bio Inc,
Tokyo, Japan). RT quantitative PCR was performed
using the 7300 Real-Time PCR System (Applied Biosys-
tems, Foster City, CA) and Platinum® SYBR® Green
qPCR SuperMix-UDG (Invitrogen). The relative mRNA
expression levels were calculated by the relative standard
curve method and normalized to 18 S rRNA.
Statistical analysis
The results are expressed as means ± SEM. Between-
groups comparisons were made, using analysis of
variance or Student’s t-test, as appropriate. A p value <
0.05 was considered significant.
Results
NEP activity in plasma of patients with ALI/ARDS
Selected characteristics of the 8 patients are shown in
Table 1. Peptidase activity was estimated by measuring
the fluorescence intensity of the cleavage product sepa-
rated from the fluorescence substrate by HPLC. Figure 1
shows the NEP activity levels in the plasma from patients
without ALI (control group) and from patients with ALI/
ARDS. The mean ± SEM peptidase activity measured
with DAGNPG in 4 control patients was 0.31 ± 0.04
pmol/min/μl in absence, and 0.09 ± 0.01 pmol/min/μli n
presence of thiorphan. In the 4 patients who developed
ALI/ARDS, the corresponding values were 0.12 ± 0.02
pmol/min/μl in absence, versus 0.04 ± 0.01 pmol/min/μl
in presence of thiorphan. The difference between the 2
groups in total activity in absence of thiorphan was sig-
nificant (p = 0.0031), whereas in presence of thiorphan
the total activity was similar in both groups (Figure 1A).
Cleavage of the fluorescent substrate was suppressed in
presence of thiorphan, a relati v e l ys p e c i f i ci n h i b i t o ro f
NEP, which inhibits a few enzymes other than NEP. The
activity of thiorphan-insensitive enzyme measured in pre-
sence of thiorphan was subtracted from the total activity
to calculate the activity of NEP. The NEP activity mea-
sured in the control and the ALI/ARDS groups was
0.22 ± 0.03 and 0.07 ± 0.02 pmol/min/μl, respectively
(Figure 1B). The difference between the 2 groups in
plasma NEP activity was also significant (p = 0.0049).
Induction of lung injury in mice
To ascertain the severity of lung injury, we examined
the lung tissue histology, the cell count and total protein
concentration in BALF, and the W/D weight ratio.
While only mild alveolar thickening and cellular infiltra-
tion were observed in the HCl-treated mice, more pro-
minent alveolar distortion and cellular infiltration were
present in the LPS-treated mice. Minimal histological
Table 1 Selected characteristics of the study patients
Group Sex Age (y) PaO2/FiO2 Lung injury
score
Outcome
Control Male 63 386 0.3 Alive
Control Female 56 325 0.3 Alive
Control Female 74 440 0.3 Alive
Control Male 70 386 0 Alive
ALI/ARDS Male 73 148 2.3 Alive
ALI/ARDS Male 77 103 2.0 Deceased
ALI/ARDS Male 71 133 2.0 Deceased
ALI/ARDS Male 64 118 2.3 Alive
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The histopathologic severity of lung injury was also
scored semi-quantitatively. The lung injury score was
significantly higher in the LPS- than in the HCl-treated
and the control mice (Figure 2B). Furthermore, the total
cell (Figure 3A) and polymorphonuclear (PMN) leuko-
cytes (Figure 3B) counts in BALF were significantly
higher in the LPS- than in the HCl-treated and the con-
trol mice, and were similar in the HCl-treated and the
control mice. The total protein concentration in the
BALF from the LPS- and HCl-treated mice was signifi-
cantly higher than in the BALF from the control mice
( F i g u r e3 C ) .T h eW / Dw e i g h tr a t i o ,a sa ni n d i c a t o ro f
lung edema, was also significantly higher in the LPS-
treated than in the control group. Although the W/D
weight ratio was higher in the HCl-treated than in the
control mice, the difference was not statistically signifi-
cant (Figure 3D).
Immuno-histochemical and immuno-cytochemical
staining for NEP
The distribution of NEP in the lungs was examined by
immuno-histochemistry, and the pattern of NEP expres-
sion in the lung of mice is shown in Figure 4. In normal
lungs, NEP staining was localized prominently in the
alveolar wall, particularly in type II and probably in type I
epithelial cells (Figure 4B), as well as in the epithelial and
smooth muscle cells of the airways, as identified previously
[19]. No staining was observed when non-immune IgG
w a su s e da san e g a t i v ec o n t r o l( F i g u r e4 A ) .A f t e rt h e
induction of ALI, the intensity of staining for NEP in the
alveolar wall appeared lower with the destruction of
the walls and sloughing of the epithelial cells. Although
the intratracheal instillation of both LPS and HCl recruited
PMN into the lung, the immuno-histochemical expression
of NEP in the injured lungs showed less intense staining
Figure 1 NEP activity in human plasma. Plasma NEP activity in Controls versus patients who developed ALI/ARDS. A. Peptidase activity in
absence (open column) or presence (filled column) of thiorphan. B. NEP activity calculated by subtraction of the thiorphan-insensitive activity
from the total activity. n = 4 in each group, *p < 0.05 vs. Control.
Figure 2 Histologic evaluation of lung injury in mice.
A. Representative lung sections from mice after single intratracheal
instillation of normal saline, or 2 ml/kg HCl, or 10 mg/kg LPS. The
LPS-treated or control mice were sacrificed at 24 h, and the HCl-
treated animals were sacrificed at 4 h after instillation, and left lung
lobes were taken from mice. The lung sections were stained with
hematoxylin and eosin and are shown at X 200 original
magnification (bar = 50 μm). B. Degree of lung injury ascertained,
using the lung injury scoring system. n = 5 in each group, *p < 0.05
vs. Control.
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Immuno-cytochemistry of the BALF cytospin preparations
also showed that the expression of NEP in infiltrating
inflammatory cells (Figure 4F) and resident alveolar
macrophages (Figure 4E) was low.
Decreased plasma NEP activity in mice with acute lung
injury
The mean ± SEM peptidase activity measured in 5 control
mice was 2.54 ± 0.10 pmol/min/μl in absence, and 1.10 ±
0.05 pmol/min/μl in presence of thiorphan. The corre-
sponding measurements in 5 LPS-treated mice were 1.61
± 0.12 and 1.11 ± 0.11 pmol/min/μl, respectively, versus
2.25 ± 0.19 and 1.15 ± 0.19 pmol/min/μl, respectively, in 3
HCl-treated mice (Figure 5A). As was observed in patients,
the plasma NEP activity was lower in 5 LPS-treated
(0.50 ± 0.05 pmol/min/μl) than in 5 control (1.45 ± 0.09
pmol/min/μl) mice. The difference in plasma NEP activity
between 3 HCl-treated (1.10 ± 0.15 pmol/min/μl) and the
5 control (1.45 ± 0.09 pmol/min/μl) mice was not statisti-
cally significant (Figure 5B).
Decreased lung NEP activity in mice with acute lung
injury
The mean ± SEM peptidase activity measured in 5 control
mice was 115 ± 8.6 pmol/min/mg in absence, and 4.32 ±
0.36 pmol/min/mg in presence of thiorphan. The corre-
sponding measurements in 4 LPS-treated mice were 54 ±
6.4 and 2.83 ± 0.21 pmol/min/mg, respectively, versus 96 ±
2.9 and 3.53 ± 0.03 pmol/min/mg, respectively, in 3 HCl-
treated mice (Figure 5C). The NEP activity level in lung tis-
sue, like in plasma, was lower in 4 mice with ALI induced
by LPS (51 ± 6.5 pmol/min/mg) than in 5 control mice
(111 ± 8.8 pmol/min/mg). The lung NEP activity levels in
3 HCl-treated (93 ± 2.8 pmol/min/mg) and 5 control mice
(111 ± 8.8 pmol/min/mg) were similar (Figure 5D).
Figure 3 BALF analysis and W/D weight ratio after induction of lung injury in mice. A. Total cell count in BALF counted by
hemocytometry. B. PMN count. Diff-Quik stain under light microscopy. C. Total protein concentration in BALF as an indicator of alveolar barrier
dysfunction. D. Pulmonary edema caused by intratracheal instillation of LPS or HCl formation measured, using the lung wet/dry (W/D) weight
ratio. n = 4 to 6 in each group, *p < 0.05 vs. Control.
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lung injury
NEP activity was detectable in the BALF of all animals.
However, in contrast to the NEP activity in plasma, that in
BALF was nearly 7-fold higher in 5 LPS-treated (0.76 ±
0.21 pmol/min/μl) than in 5 control (0.11 ± 0.01 pmol/
min/μl) mice. The NEP activity in 5 HCl-treated mice was
higher (0.26 ± 0.07 pmol/min/μl) than in the 5 control
(0.11 ± 0.01 pmol/min/μl) mice, though the difference was
not statistically significant (Figure 5E &5F). In all experi-
mental groups, the thiorphan-insensitive activity levels in
plasma, lung homogenate, and BALF were similarly low.
Decreased NEP protein in the lung tissue of mice with
acute lung injury
To determine whether the decrease in lung NEP activity
associated with ALI was due to a decrease in the
expression of NEP protein in the lung, we measured the
NEP protein content in lung homogenates using
Western immunoblotting, and found that the expression
of NEP protein in the lung in LPS-induced ALI was
< 60% of the expression measured under control condi-
tions (Figure 6).
Inhibition of NEP gene expression in the lung tissue of
mice with acute lung injury
To study the transcriptional regulation of the NEP gene,
we also measured the NEP mRNA levels in lung tissue
of mice with ALI, using semi-quantitative RT-PCR. The
NEP mRNA levels were significantly lower in the lungs
of 5 LPS-treated mice than in the lungs of 4 mice trea-
ted with saline alone (Figure 7).
Discussion
In this clinical and experimental study of ALI, the
plasma NEP activity was prominently decreased in
patients as well as in mice. In mice, the downregulation
of NEP activity in plasma and lung was associated with
a decrease in the amounts of protein and gene expres-
sion of NEP in lung tissue. We also found an increase
in NEP activity in the intra-alveolar space of mice with
ALI, in contrast to its activity in plasma. Our immuno-
histochemical observations localized the NEP protein in
the alveolar wall, where its expression was decreased by
ALI, suggesting that the injured alveolar wall is a major
source of intra-alveolar NEP activity.
In contrast to previous observations [20], we found
that the activity of NEP in plasma was lower in presence
of ALI. On the other hand, a decrease in NEP activity in
plasma has been reported during septic shock, a major
cause of ALI/ARDS [21]. To further study this apparent
conflict, we used a HPLC-fluorometric method, which
we found, in earlier studies, more sensitive to measure
the extracellular activity of NEP on the cell surface
[22,23]. The measurements made with this sensitive
method indicated that the activity of NEP in plasma was
decreased during ALI. The significant decrease in the
NEP enzymatic activity in the lung of mice with ALI
was associated with a lower level of its gene expression
in the lung, suggesting that the downregulation of NEP
activity was due to its decreased expression at the tran-
scriptional level responsible for ALI/ARDS. This down-
regulation of NEP activity may contribute to the
inactivation of the tachykinins degradation pathway and
to uncontrolled inflammation in ALI/ARDS, and in
other neurogenic respiratory diseases [9,24-26].
Our measurements of NEP activity were based on the
cleavage products of the fluorescence substrate sup-
pressed by thiorphan, a specific inhibitor widely used to
measure the activity of NEP in various samples [27].
Among the metalloproteases, angiotensin-converting
Figure 4 Immuno-histochemical and immuno-cytochemical
studies with normal IgG as a negative control (A), and with a
monoclonal antibody against NEP (B-F). A. No staining was
observed in normal lung, using non-immune IgG as negative
control. B. Prominent staining for NEP was observed in the alveolar
wall, particularly in normal type II alveolar epithelium. A decreased
immunoreactivity for NEP was apparent in the lungs, 4 h after the
instillation of HCl (C), and 24 h after the instillation of LPS (D).
Immunocytochemistry of BALF cytospin preparations showed a low
immunoreactivity for NEP in resident alveolar macrophages from
control mice (E), and infiltrating PMN leukocytes from LPS-treated
mice (F). Representative photomicrographs of lung sections and
cytospin preparations from groups of 4 or 5 mice at X 400 original
magnification (bar = 20 μm).
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insulin-degrading enzymes [30] are only slightly inhibited
by thiorphan. On the other hand, thiorphan inhibits the
activities of NEP2 [22], KELL [31], DINE [32] and PEX
[33]. We have also reported that NEP2 is sensitive to
thiorphan, though it does not cleave DAGNPG [22], a
substrate used in the present study. The substrate specifi-
cities of KELL, DINE and PEX remain to be determined.
We used 2 murine models of ALI to measure the
activity of NEP. The intratracheal instillation of LPS and
HCl aspiration are forms of lung injury which are both
neutrophil-dependent, and are characterized by inflam-
mation in the alveolar space and injury to the alveolar
barrier, associated with an increase in endothelial and
epithelial permeability [34]. Compared with the instilla-
tion of HCl, LPS caused more prominent alveolar
destruction, greater alveolar recruitment of PMN, and
more severe alveolar exudates. These differences in
severity of lung injury may be due to the measurements
made 4 h after the instillation of HCl versus 24 h after
that of LPS. The systemic downregulation and intra-
alveolar upregulation of NEP activity were also more
Figure 5 NEP activity in mice measured in plasma (A & B), lung tissue (C & D), and BALF (E & F), after the induction of lung injury in
mice. Peptidase activity of plasma (A), lung tissue (C), and BALF (E) in absence (open column) versus presence (solid column) of thiorphan. NEP
activity of plasma (B), lung tissue (D), and BALF (F) calculated by subtraction of thiorphan-insensitive from total peptidase activity. n = 3 to 5 in
each group, *p < 0.05 vs. Control.
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activity may be modulated in response to the severity of
lung injury. It is also noteworthy that the urinary excre-
tion of NEP been suggested as a new biomarker of
acute renal injury occurring after cardiac surgery [35].
Our immuno-histochemical studies showed that NEP
was expressed in the alveolar wall, most prominently in
type II alveolar epithelium, and that this expression was
decreased by the epithelial sloughing associated with ALI.
Decreased amounts of NEP protein in the lung were also
confirmed by Western immunoblot analysis. The
increased activity of NEP in BALF might, therefore,
reflect alveolar injury with secondary shedding from the
cell surface. In support of this hypothesis, it has been
suggested that the injury due the inhalation of fire smoke
causes the shedding of NEP from the airways’ epithelium
[19]. Likewise, studies of diabetic retinopathy and idio-
pathic arthritis found that the tissue injury due to the
inflammatory response can increase the extracellular
NEP activity in the interstitial space [23,36]. A recent
study has also found an elevated NEP activity in the cere-
bro-spinal fluid of patients suffering from Alzheimer’s
disease, attributed to synaptic disruption [37]. An alter-
nate explanation for the increase in NEP activity in BALF
may be the extravascular leakage of its soluble isoform in
response to the alveolar-capillary barrier injury.
We did not exclude intra-alveolar inflammatory cells,
including PMN, as the source of increased NEP activity
in BALF. Previous studies have observed the expression
of NEP on the surface of PMN [38,39]. In addition, the
NEP activity was higher in the LPS-treated mice, in
which the recruitment of PMN into the air-space was
increased. However, our immuno-histochemical and
immuno-cytochemical analyses showed prominent NEP
staining neither on inflammatory cells recruited into the
air-space, nor on resident alveolar macrophages. A pre-
vious study found that the expression of NEP on circu-
lating PMN was reduced in humans challenged with
LPS [40]. Thus, the NEP expression was most likely
down-regulated on the PMN that were recruited and
activated during ALI/ARDS.
Study limitations
The major limitations of our clinical study are its small
sample size and retrospective design, due to our intent to
study a homogeneous population of postoperative patients
with ALI/ARDS. Therefore, we supplemented our investi-
gations of the regulatory mechanisms of NEP activity by
adding the mice experiments. Despite the limited number
of patients, this study offers new insights into the patho-
genesis of ALI/ARDS. A larger, randomized trial will be
needed to confirm the existence of a correlation between
NEP activity and severity of ALI/ARDS.
Conclusions
We found, in ALI/ARDS, a significant decrease in the
plasma activity of NEP, while its intra-alveolar activity
was significantly increased. The identification of the
enzymatic regulation associated with NEP would broaden
our understanding of the role it plays in ALI/ARDS.
Figure 6 Relative expression of NEP protein in lung tissue.
A. Representative whole lung tissue immunoblot for NEP and
b-actin, in a control preparation versus 24 h after the instillation of
LPS. B. Densitometric measurements of NEP expression in 5 control
versus 5 LPS-treated mice. *p < 0.05.
Figure 7 Relative mRNA expression of NEP in lung tissue.
Relative gene expression patterns of NEP in whole lung tissue, 24 h
after the instillation of LPS versus saline (Control), analyzed by
quantitative RT-PCR. The results are expressed as relative amounts
normalized for 18 S rRNA. n = 4 or 5 mice in each group. *p < 0.05.
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distress syndrome; HCl: hydrochloric acid; LPS: lipopolysaccharide; CALLA:
common acute lymphoblastic leukemia antigen; BALF: broncho-alveolar
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